Portugal center treats 1,000 daily
A new immunotherapy cancer center in Portugal is reportedly treating about 1,000 patients every day, which signals major local capacity for cutting-edge cancer care and could change regional referral patterns (x.com). That scale matters because concentrated treatment hubs can speed access to trials and specialist teams that individual hospitals often can’t maintain alone (x.com).
Immunotherapy is cancer treatment that tells the body’s own immune system to spot and attack tumor cells, instead of only cutting, burning, or poisoning them. The United States National Cancer Institute describes it as treatment that helps the immune system fight cancer. (cancer.gov) That kind of treatment is hard to run at scale because patients need repeated visits, close monitoring, and doctors who know how to handle immune side effects that can hit the lungs, liver, skin, or gut. The American Cancer Society says immunotherapy often requires careful preparation and follow-up because reactions differ from patient to patient. (cancer.org) Portugal’s new headline is that a Lisbon cancer unit tied to Hospital de Santa Maria is now being presented as a major hub for these newer therapies and early drug studies. Portuguese public broadcaster RTP reported on April 6, 2026 that the center is part of one of the world’s largest oncology trial consortia. (rtp.pt) This did not appear overnight. In August 2022, the START Center for Cancer Care said it would open Portugal’s first early-phase oncology clinical trials unit in Lisbon through an agreement with Hospital de Santa Maria, the country’s largest university hospital. (startresearch.com) Early-phase trials are the first tests of a new cancer drug in people, usually focused on dose, safety, and the first signs that the drug is doing anything at all. The National Cancer Institute groups Phase 0, Phase I, and some Phase II studies in this early stage of drug development. (grants.nih.gov) That matters for patients who have run out of standard options, because these units are often the only place offering medicines before they reach the normal hospital system. START said in 2022 that the Lisbon facility would treat patients who had exhausted all other known alternatives. (startresearch.com) Portugal has also been building the regulatory plumbing behind this. Infarmed, the national medicines regulator, said in January 2026 that 209 clinical trials were submitted in Portugal in 2025, up from 204 in 2024 and 176 in 2023. (infarmed.pt) RTP added one more number that helps explain the rush: over the last three years, Infarmed authorized 591 new clinical trials, and about one third were in cancer. That means oncology is not a side project in Portugal’s research system anymore; it is one of the main lanes. (rtp.pt) A center seeing around 1,000 patients a day is not just a big clinic. At that volume, you can keep specialist nurses, trial pharmacists, imaging teams, and doctors for rare tumor types in one place instead of scattering them across smaller hospitals that may only see a handful of similar cases. (startresearch.com) Lisbon is also already a destination for cross-border cancer care. The Champalimaud Clinical Centre says patients travel from around the world to Lisbon for cancer treatment and that its medical staff includes doctors from more than 10 countries. (fchampalimaud.org) So the Portugal story is not only about one building treating a lot of people. It is about Lisbon turning into a referral point where a patient can move from standard oncology care into an experimental drug study without leaving the same city, and Portugal now has the trial numbers and hospital infrastructure to make that plausible. (rtp.pt)
